H.R. 9455 aims to amend the Internal Revenue Code of 1986 by restricting eligibility for the premium tax credit. Under this bill, only individuals who are enrolled in qualified health plans from health insurance issuers that offer at least one qualified health plan meeting certain criteria would be eligible for the premium tax credit. This change is likely intended to ensure that tax credits are provided only for plans that meet specific standards.
Some media outlets have reported positively on H.R. 9455, highlighting that the bill could lead to better quality health insurance options by ensuring that only those plans which meet certain standards are eligible for tax credits. Supporters argue that this could promote healthier competition among insurers and improve overall healthcare outcomes for consumers.
Critics of H.R. 9455 have expressed concerns that the bill may limit access to affordable healthcare for many individuals. Negative media coverage has pointed out that by narrowing the eligibility for premium tax credits, the bill could disproportionately affect low-income individuals and those with pre-existing conditions, potentially leading to higher out-of-pocket costs for many Americans.
While there are no direct industry overlaps between the sponsor's top donor industries and the subject matter of H.R. 9455, the lobbying activity in the healthcare sector raises some concerns. Vertex Pharmaceuticals, which has contributed $60,000, is a significant player in the pharmaceutical industry, and their interests may align with the implications of this bill on health insurance eligibility and premium tax credits. Additionally, the Mayo Clinic, a major healthcare provider, is also involved in lobbying but has not disclosed specific amounts. This lack of transparency could obscure potential influences on the bill's outcomes. Voters should be aware that while direct financial conflicts are not evident, the indirect influence of major healthcare stakeholders could affect the legislative process.
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | MARSHALL & POPP, LLC | $60,000 |
| SUN PHARMACEUTICAL INDUSTRIES, INC. | MARSHALL & POPP, LLC | $60,000 |
| SANOFI U.S. SERVICES, INC. | MARSHALL & POPP, LLC | $60,000 |
| WAYFINDER GROUP (OBO RESEARCH CORPORATION OF THE UNIVERSITY OF HAWAII) | RED MAPLE CONSULTING, LLC | $40,000 |
| ECKERD CONNECTS | KOUNTOUPES DENHAM CARR & REID, LLC | $30,000 |
| SMART APPROACHES TO MARIJUANA | OFF HILL STRATEGIES L.L.C. | $20,000 |
| FEDERATION OF ELECTRIC POWER COS OF JAPAN | GEORGE H. DENISON | $10,000 |
| MAYO CLINIC | MCDERMOTT WILL & SCHULTE LLP | undisclosed |
| VERIZON COMMUNICATIONS, INC. | MARSHALL & POPP, LLC | undisclosed |
| THE BIG TEN CONFERENCE, INC. | MARSHALL & POPP, LLC | undisclosed |
| THE BIG 12 CONFERENCE, INC. | MARSHALL & POPP, LLC | undisclosed |
| SOUTHEASTERN CONFERENCE | MARSHALL & POPP, LLC | undisclosed |
| PAC-12 CONFERENCE | MARSHALL & POPP, LLC | undisclosed |
| ATLANTIC COAST CONFERENCE | MARSHALL & POPP, LLC | undisclosed |
| SAPPHIRE DIGITAL | MARSHALL & POPP, LLC | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Aaron Bean, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
